Partnership to End Hiv, Aids & Hepatitis
Coalition of non-profit organizations supporting funding and access to HIV/AIDS treatments
Based in FL
AI Overview
With $620K in lobbying spend across 16 quarterly filings, Partnership to End Hiv, Aids & Hepatitis is an active lobbying client. Their lobbying covers 1 issue area. Active from 2022 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2022 | $160K |
| 2023 | $150K |
| 2024 | $160K |
| 2025 | $150K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Partnership to End Hiv, Aids & Hepatitis disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support.
H.R. 8295, FY23 Labor HHS Appropriations bill, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support.
H.R. 8295, FY23 Labor HHS Appropriations bill, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support; Federal Policy and Congress
H.R. 2617, the FY23 Consolidated Appropriations Act, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support; Federal Policy and Co
FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (draft bill); provisions related to funding for Ending the HIV Epidemic Initiative, Ryan Wh
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.